

Supplementary Table 2. Factors associated with COVID-19 in patients with RA

Variable	Unadjusted OR (95% CI)	p value	Adjusted OR (95% CI)	p value
Age ≥ 60 years	0.99 (0.49–2.01)	0.976	0.90 (0.43–1.89)	0.771
Female sex	0.72 (0.30–1.73)	0.466	0.75 (0.30–1.88)	0.537
Comorbidities				
Hypertension	1.86 (0.41–8.47)	0.421		
Cardiovascular disease	0.72 (0.09–5.51)	0.748		
Chronic lung disease	5.08 (0.98–26.19)	0.052	6.07 (1.10–33.59)	0.039
Current medications				
Glucocorticoid	0.84 (0.40–1.77)	0.641		
Glucocorticoid dose ≥ 10 mg/day	0.99 (0.47–2.08)	0.967		
Hydroxychloroquine	1.66 (0.81–3.41)	0.169	1.51 (0.69–3.32)	0.304
Methotrexate	1.39 (0.65–2.99)	0.400		
Sulfasalazine	1.87 (0.91–3.84)	0.087	1.59 (0.72–3.50)	0.252
Leflunomide	1.13 (0.51–2.50)	0.761		
Tacrolimus	0.54 (0.13–2.32)	0.408		
Abatacept	5.08 (0.98–26.19)	0.052	5.49 (1.02–29.66)	0.048

COVID-19, coronavirus disease 2019; RA, rheumatoid arthritis; OR, odds ratio; CI, confidence interval.